While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
NEW YORK -- New York City Mayor Eric Adams pleaded innocent Friday to federal bribery charges, rejecting claims that he accepted overseas travel, campaign cash and other perks from foreign interests ...
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
The conference also served to educate the attendees about UAMS' Odyssey Clinic. Dr. Craig Jones, the clinic's program manager, said it opened July 1 and works with schizophrenia patients 16 years or ...
Despite schizophrenia, the jury rejected the defense's contention that the man was insane at the time of the 2021 attack.
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Dr. James Lawler, of the University of Nebraska’s Global Center for Health Security, on trying to pick out the bird flu virus from among myriad other viruses present during the time of year when ...
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
California Gov. Gavin Newsom on Friday signed a package of legislation meant to strengthen mental health and substance abuse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback